Inogen, Inc (INGN) EVP Sells $280,875.00 in Stock

Inogen, Inc (NASDAQ:INGN) EVP Matt Scribner sold 2,500 shares of Inogen stock in a transaction dated Monday, November 13th. The shares were sold at an average price of $112.35, for a total transaction of $280,875.00. The sale was disclosed in a legal filing with the SEC, which is available through this link.

Matt Scribner also recently made the following trade(s):

  • On Thursday, October 12th, Matt Scribner sold 2,500 shares of Inogen stock. The shares were sold at an average price of $93.88, for a total transaction of $234,700.00.
  • On Monday, September 11th, Matt Scribner sold 2,500 shares of Inogen stock. The shares were sold at an average price of $103.23, for a total transaction of $258,075.00.
  • On Friday, August 18th, Matt Scribner sold 2,500 shares of Inogen stock. The shares were sold at an average price of $92.45, for a total transaction of $231,125.00.

Shares of Inogen, Inc (NASDAQ:INGN) traded down $1.95 during trading on Friday, reaching $118.26. 155,058 shares of the company’s stock traded hands, compared to its average volume of 166,610. The stock has a market capitalization of $2,450.00, a PE ratio of 96.94, a PEG ratio of 5.01 and a beta of 0.98. Inogen, Inc has a twelve month low of $60.02 and a twelve month high of $124.90.

Inogen (NASDAQ:INGN) last issued its earnings results on Tuesday, November 7th. The medical technology company reported $0.33 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.29 by $0.04. The business had revenue of $69.00 million during the quarter, compared to analysts’ expectations of $63.55 million. Inogen had a net margin of 11.36% and a return on equity of 13.37%. The business’s revenue for the quarter was up 26.8% compared to the same quarter last year. During the same period in the previous year, the company earned $0.25 earnings per share. analysts predict that Inogen, Inc will post 1.19 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: This article was originally published by Community Financial News and is the property of of Community Financial News. If you are viewing this article on another publication, it was illegally copied and reposted in violation of United States and international copyright & trademark laws. The original version of this article can be read at https://www.com-unik.info/2017/11/18/inogen-inc-ingn-evp-sells-280875-00-in-stock.html.

A number of institutional investors have recently modified their holdings of INGN. Schroder Investment Management Group purchased a new position in Inogen in the second quarter worth about $132,000. Ameritas Investment Partners Inc. raised its holdings in Inogen by 6.1% in the second quarter. Ameritas Investment Partners Inc. now owns 1,495 shares of the medical technology company’s stock worth $143,000 after buying an additional 86 shares during the last quarter. Sei Investments Co. raised its holdings in shares of Inogen by 38.1% during the second quarter. Sei Investments Co. now owns 1,606 shares of the medical technology company’s stock valued at $153,000 after purchasing an additional 443 shares during the last quarter. Victory Capital Management Inc. raised its holdings in shares of Inogen by 17.8% during the second quarter. Victory Capital Management Inc. now owns 2,036 shares of the medical technology company’s stock valued at $194,000 after purchasing an additional 307 shares during the last quarter. Finally, Pinebridge Investments L.P. raised its holdings in shares of Inogen by 1.6% during the second quarter. Pinebridge Investments L.P. now owns 2,143 shares of the medical technology company’s stock valued at $204,000 after purchasing an additional 33 shares during the last quarter.

A number of research analysts recently issued reports on the stock. Zacks Investment Research raised shares of Inogen from a “hold” rating to a “buy” rating and set a $131.00 price target for the company in a research report on Thursday, November 9th. Leerink Swann reissued an “outperform” rating and set a $120.00 price target (up from $115.00) on shares of Inogen in a research report on Wednesday, November 8th. Needham & Company LLC lifted their price target on shares of Inogen from $108.00 to $125.00 and gave the company a “strong-buy” rating in a research report on Wednesday, November 8th. Piper Jaffray Companies reissued a “hold” rating and set a $90.00 price target on shares of Inogen in a research report on Tuesday, September 12th. Finally, BidaskClub raised shares of Inogen from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, August 8th. Three equities research analysts have rated the stock with a hold rating, three have issued a buy rating and two have assigned a strong buy rating to the company. The stock has an average rating of “Buy” and an average target price of $103.14.

Inogen Company Profile

Inogen, Inc is a medical technology company. The Company develops, manufactures and markets portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The Company’s Inogen One systems concentrate the air around the patient to offer a single source of supplemental oxygen anytime, anywhere with a portable device.

Insider Buying and Selling by Quarter for Inogen (NASDAQ:INGN)

What are top analysts saying about Inogen Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Inogen Inc and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit